Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,637.08
(
2.01%
)
US TECH 100
23,726.80
(
1.91%
)
Dow Jones
46,588.10
(
2.22%
)
Brent Oil
97.97
(
-9.40%
)
Bitcoin
71,473.99
(
5.36%
)
News Focus
News Focus
Post# of 30495
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 25260

Tuesday, 05/03/2022 1:57:31 PM

Tuesday, May 03, 2022 1:57:31 PM

Post# of 30495
ZBH 1Q22 results—2022 guidance:

https://investor.zimmerbiomet.com/news-and-events/news/2022/05-03-2022-113116507

1Q22 sales were +7% YoY in constant currency. 1Q22 non-GAAP EPS was $1.61, excluding the from the ZIMV segment during Jan and Feb, prior to the 3/1/22 spin-off. This compares to $1.71 non-GAAP EPS in 1Q21 (which included the ZIMV segment).

Elective-procedure recovery was stronger than the company expected. In Mar 2022 (but not Jan and Feb), procedure volume was higher than 2019 (pre-pandemic) levels.

2022 non-GAAP EPS guidance was raised and tightened to $6.65-$6.85 (from the prior range of $6.40-6.80).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today